FDA approves intramuscular administration for Merck’s MMRV family of vaccines

angelp/iStock via Getty Images

• Merck (NYSE:MRK) announces that the FDA has approved the addition of the intramuscular (IM) route of administration to the United States Product Insert (USPI) for Merck’s MMRV family of vaccines: M-M-R_II, VARIVAX, and ProQuad.
• Until